Evidence map›Paper›PMID 35705204›Full record

Trial reportJournal of psychiatry & neuroscience : JPN

Infralow neurofeedback in the treatment of substance use disorders: a randomized controlled trial.

Karin Berle Gabrielsen, Thomas Clausen, Siri Håvås Haugland, Stig Arvid Hollup, John-Kåre Vederhus

Registry-linked trialOpen access · diamondAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of psychiatry & neuroscience : JPN. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03356210 (Quantitative Electroencephalography and Neurofeedback Training for the Treatment of Substance Use Disorders), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03356210 nacompletednot on this map

Quantitative Electroencephalography and Neurofeedback Training for the Treatment of Substance Use Disorders: A Randomized Controlled Trial

TypeinterventionalSponsorSorlandet Hospital HFRan2017 to 2021Enrolled93ConditionsSubstance Use DisordersArmsNeurofeedback
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Quality of life measures in treatment for active substance misuse: a scoping review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025
    Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Karin Berle GabrielsenFrom the Addiction Unit, Sørlandet Hospital, Kristiansand, Norway (Gabrielsen, Clausen, Vederhus); the Norwegian Centre for Addiction Research (SERAF), University of Oslo, Oslo, Norway (Clausen); the Department of Psychosocial Health, University of Agder, Grimstad, Norway (Haugland); the Norwegian University of Science and Technology, Trondheim, Norway (Hollup) karin.berle.gabrielsen@sshf.no.
Thomas ClausenFrom the Addiction Unit, Sørlandet Hospital, Kristiansand, Norway (Gabrielsen, Clausen, Vederhus); the Norwegian Centre for Addiction Research (SERAF), University of Oslo, Oslo, Norway (Clausen); the Department of Psychosocial Health, University of Agder, Grimstad, Norway (Haugland); the Norwegian University of Science and Technology, Trondheim, Norway (Hollup).
Siri Håvås HauglandFrom the Addiction Unit, Sørlandet Hospital, Kristiansand, Norway (Gabrielsen, Clausen, Vederhus); the Norwegian Centre for Addiction Research (SERAF), University of Oslo, Oslo, Norway (Clausen); the Department of Psychosocial Health, University of Agder, Grimstad, Norway (Haugland); the Norwegian University of Science and Technology, Trondheim, Norway (Hollup).
Stig Arvid HollupFrom the Addiction Unit, Sørlandet Hospital, Kristiansand, Norway (Gabrielsen, Clausen, Vederhus); the Norwegian Centre for Addiction Research (SERAF), University of Oslo, Oslo, Norway (Clausen); the Department of Psychosocial Health, University of Agder, Grimstad, Norway (Haugland); the Norwegian University of Science and Technology, Trondheim, Norway (Hollup).
John-Kåre VederhusFrom the Addiction Unit, Sørlandet Hospital, Kristiansand, Norway (Gabrielsen, Clausen, Vederhus); the Norwegian Centre for Addiction Research (SERAF), University of Oslo, Oslo, Norway (Clausen); the Department of Psychosocial Health, University of Agder, Grimstad, Norway (Haugland); the Norwegian University of Science and Technology, Trondheim, Norway (Hollup).
University of Agder · NOUniversity of Oslo · NOSørlandet Sykehus · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInfralow neurofeedback (ILF-NF) was recently developed as a subtype of traditional, frequency-based neurofeedback that targets cerebral rhythmic activity below 0.5 Hz and improves brain self-regulation. The efficacy of ILF-NF in the treatment of substance use disorder has not yet been evaluated, but clinical evidence suggests that it may prevent relapse by improving functioning in various life domains. The current study aimed to fill this research gap and extend empirical evidence related to this issue.

methodsNinety-three patients with substance use disorders at an outpatient unit in Norway were randomized to receive 20 sessions (30 minutes each) of ILF-NF training combined with treatment as usual (TAU), or TAU alone. The primary outcome was quality of life post-treatment as an overall measure of functioning. We analyzed between-group differences using Student

resultsWe found no significant differences in quality of life between groups. We found similar nonsignificant results for most of the secondary outcome measures, including drug use, sleep, anxiety and depression. Compared to TAU, the ILF-NF + TAU group reported significantly lower restlessness scores post-treatment (mean difference -1.8, 95 % confidence interval -3.1 to -0.5;

conclusionILF-NF offered limited additional benefit when combined with TAU, except in the area of restlessness. Future studies could further investigate the relationship between ILF-NF, restlessness and substance use in targeted subpopulations to illuminate relapse mechanisms. CLINICAL

trial registrationClinicalTrials.gov: NCT03356210.

Indexed as

NeurofeedbackSubstance-Related DisordersHumansPsychomotor AgitationQuality of LifeRecurrenceTreatment Outcome

Identifiers

PMID35705204
PMCPMC9343117
OpenAlexW4282917255

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.